MT1002 for Injection for Acute Coronary Syndrome

"This clinical trial is in search of 24 people diagnosed with acute coronary syndrome, aged between 18 and 80. Exclusion criteria include: post-menopausal or surgically sterile patients; males who have not had a vasectomy for at least three months prior to dosing and are sexually active with fertile partners must agree to use reliable contraception methods from commencement of treatment until 90 days after the study's end; those without any serious neurological, cardiovascular, respiratory, immunological etc illnesses within four weeks before drug administration; non-smokers with BMI greater than 18.0 and lesser than 40.0 kg/m2 as well as body weight above"

"This research initiative is searching for individuals between 18 and 80 years of age."

"According to the information provided on clinicaltrials.gov, this research study is recruiting participants now. The trial was initially posted on April 15th 2022 and revised most recently on October 24th 2022."

"Affirmative, the information on clinicaltrials.gov confirms that this experiment is presently enrolling patients. It was first made available on April 15th 2022, and last edited two months ago in October 24th 2022. The trial requires a total of 24 study participants to be recruited at one site."

"Our team at Power assigned MT1002 for Injection a rating of 1, as the current evidence suggests it has limited efficacy and safety data from Phase 1 trials."